Business
EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting
WATERTOWN, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to
About this update from Eyepoint, Inc.
[{"type":"text","content":"WATERTOWN, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for chronic, non-infectious uveitis affecting the posterior segment of the eye have been accepted for presentation at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting being held October 12 – 15, 2019 in San Francisco, CA. One abstract was accepted for oral presentation at the Retina Subspecialty Day program of AAO on October 11, 2019.\n “Feedback received from uveitis specialists and patients as part of our ongoing U.S. commercial launch of YUTIQ continues to reinforce the treatment limitations of corticosteroids for chronic, non-infectious uveitis affecting the posterior segment of the eye,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. “We believe YUTIQ provides a highly differentiated product profile compared to existing therapies due to its convenient office administration and consistent dosing for up to 36-months. Additional data to be shared at AAO provide further evidence of the long-lasting activity of YUTIQ for this difficult to treat ocular disease that can lead to blindness.” Details for AAO presentations are as follows: Oral Presentation Title: Effect of Fluocinolone Acetonide Insert on the Presence of Uveitic Macular Edema: Outcomes at 36 MonthsPresenter: Quan Nguyen, M.D., M.Sc., Professor of Ophthalmology, Byers Eye Institute, Stanford UniversitySession Title: RET08 - Section V: Uveitis, Retina Subspecialty DayDate and Time: Friday, October 11, 2019; 1:58-2:05 PM PDT Poster Presentation Title: PO532 Fluocinolone Acetonide Intravitreal Insert for Noninfectious Posterior Uveitis: Analysis of Significant IOP ElevationPresenter: Michael Singer, M.D., Clinical Professor of Ophthalmology, University of Texas Health Science CenterSession Title: PD40 - ePoster Discussion: UveitisDate and Time: Monday, October 14, 2019; 12:30-1:30 PM PDTPanel Discussion Time: 1:00 – 1:30 PM PDT About YUTIQ® YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic, non-infectious uveitis a...